Emami Limited

rs,

al Street - 400 051 Mumbai Scrip Code: EMAMILTD Mumbai Scrip Code: - 400 001 531162 Dear Sirs, Pursuant to Provision of Regulation 30 of the SEBI (Listing Obligations and Disclosure Requireme

₹ 75.90

n volume terms. All Household penetration data (HHP) as per MAT Dec 2021 Conversion rate : 1 US$ = ₹ 75.90/- (As on 31st March 2022) All share price data as on 31st March 2022 THIS PRESENTATION IS SEGREG

38x

in 4.9 mn retail outlets 6 Entered mainstream categories to address a wider consumer base 38x returns since the IPO in 2005 Market capitalisation of ~US$2.6 bn BOARD OF DIRECTORS PROMOTE

3%

-Banker Mamta Binani Advocate & Insolvency Professional BUSINESS STRUCTURE Revenue split in % 3% 16% 3% 15% 8 81% 82% FY21 Domestic: 81% International business: 16% Institutional business:

16%

ker Mamta Binani Advocate & Insolvency Professional BUSINESS STRUCTURE Revenue split in % 3% 16% 3% 15% 8 81% 82% FY21 Domestic: 81% International business: 16% Institutional business: 3% F

15%

a Binani Advocate & Insolvency Professional BUSINESS STRUCTURE Revenue split in % 3% 16% 3% 15% 8 81% 82% FY21 Domestic: 81% International business: 16% Institutional business: 3% FY22 Domes

81%

Advocate & Insolvency Professional BUSINESS STRUCTURE Revenue split in % 3% 16% 3% 15% 8 81% 82% FY21 Domestic: 81% International business: 16% Institutional business: 3% FY22 Domestic: 82%

82%

cate & Insolvency Professional BUSINESS STRUCTURE Revenue split in % 3% 16% 3% 15% 8 81% 82% FY21 Domestic: 81% International business: 16% Institutional business: 3% FY22 Domestic: 82% Inte

₹800 crore

usiness: 3% FY22 Domestic: 82% International business: 15% Institutional business: 3% KEY BRANDS ₹800 crore+ ₹700 crore+ ₹500 crore+ ₹300 crore+ Pain Balms, Healthcare products in OTC, Generics & Ethic

₹700 crore

FY22 Domestic: 82% International business: 15% Institutional business: 3% KEY BRANDS ₹800 crore+ ₹700 crore+ ₹500 crore+ ₹300 crore+ Pain Balms, Healthcare products in OTC, Generics & Ethicals Cool Oi

₹500 crore

: 82% International business: 15% Institutional business: 3% KEY BRANDS ₹800 crore+ ₹700 crore+ ₹500 crore+ ₹300 crore+ Pain Balms, Healthcare products in OTC, Generics & Ethicals Cool Oils and Cool T

₹300 crore

tional business: 15% Institutional business: 3% KEY BRANDS ₹800 crore+ ₹700 crore+ ₹500 crore+ ₹300 crore+ Pain Balms, Healthcare products in OTC, Generics & Ethicals Cool Oils and Cool Talc Antisept

“‘Brilliare” becomes subsidiary Buyback of Shares for ₹162 cr; Acquired Dermicool brand BUSINESS HIGHLIGHTS • One of the fastest growing personal and healthcare businesses in India  Revenues growing at a 10-year CAGR of 9%  EBIDTA growing at a 10 year CAGR of 12%  Profits before Tax* growing at a 10-year CAGR of 9% • Superior Industry Margins-  Gross Margins at 66.2%  EBIDTA Margins before A&P at 46.2%  EBIDTA Margins at 29.8% • • • • • Production in tax-free zones.”

“Project Sirius Rolled out app for Upsell & Cross Sell enabler for Frontline Sales force.”

Scrip Code

2

Date

1

Date

1st June, 2022 The Manager - Listing BSE Limited Phiroze Jeejeebhoy Towers Dalal Street - 400 051 Mumbai

Scrip Code

- 400 001 531162 Dear Sirs, Pursuant to Provision of Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we Company's Overview June 2022. are enclosing herewith copy of Presentation on The aforesaid information is also given on the website of the company www.emamiltd.in This is for your information and records. Thanking you, Yours faithfully, For Emami Limited 4w· Ashok Purohit Assistant Company Secretary (Encl.: As above) phone: 91336613 6264 6600 e-mail: contact@emamigroup.comwebsite:www.emamiltd.in regd. office tele tax: 91336613 : 687 anandapur e. m. bypass kolkata 700107 india GIN: L63993VVB1983PLC036030 REFUELLING ITS GROWTH SPIRIT EMAMI LIMITED COMPANY OVERVIEW JUNE 2022 DISCLAIMER Some of the statements made in this presentation may look forward looking information that involves number of risks and uncertainties. Such statements are based on certain assumptions, estimates, projections or plans that are inherently subject to significant